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Abstract
Background: The cystine/glutamate antiporter (xc-) has been implicated in several neurological disorders and,
specifically, in multiple sclerosis (MS) as a mediator of glutamate excitotoxicity and proinflammatory immune responses.
We aimed to evaluate an xc-specific positron emission tomography (PET) radiotracer, (4S)-4-(3-[18F]fluoropropyl)-L-
glutamate ([18F]FSPG), for its ability to allow non-invasive monitoring of xc- activity in a mouse model of MS.
Methods: Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice by subcutaneous injection
of myelin oligodendrocyte glycoprotein (MOG35–55) peptide in complete Freund’s adjuvant (CFA) followed by pertussis
toxin. Control mice received CFA emulsion and pertussis toxin without MOG peptide, while a separate cohort of naïve
mice received no treatment. PET studies were performed to investigate the kinetics and distribution of [18F]FSPG in
naïve, control, pre-symptomatic, and symptomatic EAE mice, compared to 18F-fluorodeoxyglucose ([18F]FDG). After final
PET scans, each mouse was perfused and radioactivity in dissected tissues was measured using a gamma counter.
Central nervous system (CNS) tissues were further analyzed using ex vivo autoradiography or western blot. [18F]FSPG
uptake in human monocytes, and T cells pre- and post-activation was investigated in vitro.
Results: [18F]FSPG was found to be more sensitive than [18F]FDG at detecting pathological changes in the spinal cord
and brain of EAE mice. Even before clinical signs of disease, a small but significant increase in [18F]FSPG signal was
observed in the spinal cord of EAE mice compared to controls. This increase in PET signal became more pronounced in
symptomatic EAE mice and was confirmed by ex vivo biodistribution and autoradiography. Likewise, in the brain of
symptomatic EAE mice, [18F]FSPG uptake was significantly higher than controls, with the largest changes observed in
the cerebellum. Western blot analyses of CNS tissues revealed a significant correlation between light chain of xc- (xCT)
protein levels, the subunit of xc- credited with its transporter activity, and [18F]FSPG-PET signal. In vitro [18F]FSPG uptake
studies suggest that both activated monocytes and T cells contribute to the observed in vivo PET signal.
Conclusion: These data highlight the promise of [18F]FSPG-PET as a technique to provide insights into neuroimmune
interactions in MS and the in vivo role of xc- in the development and progression of this disease, thus warranting
further investigation.
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Background
The key pathological hallmarks of multiple sclerosis
(MS) include demyelination, oligodendrocyte cell death,
microglial activation, peripheral immune cell infiltration,
and axonal degeneration in the central nervous system
(CNS) [1]. Over the past two decades, an increasing
amount of data has emerged suggesting that oxidative
stress also plays a key role in the pathogenesis of MS [2].
It is known that upregulation of cystine/glutamate anti-
porter (xc-) is an oxidative stress response by cells in an
attempt to increase availability of the glutathione biosyn-
thesis precursor cystine for improved reactive oxygen
species (ROS) detoxification [3]. Under certain patho-
logical conditions accompanied by dysregulation of
glutamate homeostasis, increased cystine influx through
xc- leads to elevated extracellular levels of the neuro-
transmitter glutamate [4]. Glutamate excitotoxicity is
known to contribute to oligodendrocyte and tissue dam-
age in MS by over-activating glutamate receptors [5]. In
2011, Pampliega and colleagues reported that the light
chain of the heterodimeric xc- transmembrane protein
(known as xCT) responsible for its transporter activity is
upregulated in the spinal cord of mice and rats with ex-
perimental autoimmune encephalomyelitis (EAE), the
most widely characterized rodent model of MS, as well
as human MS postmortem tissue [6]. A recent study by
Merckx and colleagues suggests that it is the peripheral
immune cells expressing xc-, known to infiltrate the
CNS in MS, rather than the resident immune cells that
directly contribute to glutamate release and excitotoxi-
city [7].
Recently, Martin and colleagues described the use of
a previously reported 18F-labeled small molecule xc-
substrate—known as (4S)-4-(3-[18F]fluoropropyl)-L-glu-
tamate ([18F]FSPG)—for imaging xc- activity in EAE
rats using PET [8]. While these studies highlighted the
promise of [18F]FSPG-PET imaging as a non-invasive
biomarker of MS disease status and for therapy moni-
toring, the authors did not investigate the relationship
between the observed increased PET signal in EAE rats
and levels of target expression. Here, we propose to ex-
pand upon our previous work with [18F]FSPG in MS
rodent models [9] by conducting the first investigation
of correlation between [18F]FSPG-PET signal and levels
of xCT in EAE, alongside human immune cell uptake
studies, with the aim of improving understanding of the
molecular and cellular significance of [18F]FSPG signal
in EAE and MS. Since the Lewis rat model of EAE does
not undergo demyelination [10] (a hallmark feature of
human MS), we conducted [18F]FSPG-PET imaging in
an EAE mouse model that does undergo demyelination,
with the aim of obtaining clinically relevant and trans-
latable information concerning this tracer’s potential
use in MS.
The primary goal of the present studies was therefore
to evaluate [18F]FSPG for its ability to detect alterations
in xc- antiporter activity in EAE mice at different stages
of disease via PET imaging and to correlate PET findings
with xCT protein levels in affected CNS tissues.
Methods
Study design
Since there were no prior reports of [18F]FSPG-PET im-
aging in EAE mice, we began by performing pilot dy-
namic PET/CT imaging studies in symptomatic EAE
(score 1.0–3.5) versus naive mice to gain an understand-
ing of the in vivo distribution and kinetics of [18F]FSPG.
Next, we compared the uptake pattern of [18F]FSPG
with that of the widely used clinical PET tracer, 18F-
fluorodeoxyglucose ([18F]FDG), previously shown to
have increased uptake in activated immune cells and/or
CNS lesions in EAE rodent models and MS patients
[11, 12]. The utility of [18F]FDG-PET in MS is limited
due to the high/fluctuating basal uptake of this radio-
tracer in CNS tissues of MS patients, which generates
ambiguity in the detection of [18F]FDG accumulation in
lesions [13, 14]; hence, the need to assess whether
[18F]FSPG uptake could serve as a more sensitive
marker of pathological changes in CNS tissues of EAE
mice.
Following these initial comparison studies, we
performed longitudinal experiments to characterize
[18F]FSPG uptake in CNS tissues at the pre-symptomatic
versus symptomatic stages of EAE disease and to examine
the relationship between imaging signal and xCT protein
levels. Lastly, as a prelude to future clinical studies with
[18F]FSPG, we investigated the uptake of [18F]FSPG in ac-
tivated human monocytes and T cells—which have both
been implicated in the pathogenesis of EAE/MS. We
chose to use human cells for these studies to add a trans-
lational dimension to our work with the goal of obtaining
insights into the extent that specific immune cell types
contribute to [18F]FSPG-PET signal in MS.
Radiochemistry
[18F]FSPG was synthesized according to previous
methods [15] in 45–70 min with a radiochemical yield
of 36 ± 17% (decay-corrected to end of bombardment),
specific activity 48.47 ± 16.65 GBq/μmol (end of synthe-
sis) and radiochemical purity > 90% (n = 13). Clinical
grade [18F]FDG was supplied by the Radiochemistry
Facility at Stanford University.
EAE immunization
Animal procedures were approved by Stanford University
Institutional Animal Care and Use Committee. Female
C57BL/6 mice (10–12 weeks old) were immunized
subcutaneously with 100 μg of myelin oligodendrocyte
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glycoprotein fragment35–55 (MOG35–55) peptide (Stanford
Protein and Nucleic Acid Biotechnology Facility) emulsi-
fied in complete Freund’s adjuvant (CFA; 200 μg mycobac-
terium tuberculosis, BD Difco Adjuvants). Mice received
an intravenous injection of 100 ng pertussis toxin (List
Biological Laboratories Inc.) at the time of immunization
and 48 h later. Control mice received a CFA/PBS emul-
sion without MOG peptide and the same amount of per-
tussis toxin. Mice were weighed, examined daily for
clinical signs of EAE, and scored according to the follow-
ing criteria: score of 0, no paralysis; 0.5, partial loss of tail
tone; 1, complete loss of tail tone; 1.5, complete tail par-
alysis accompanied by weakness in one hind limb; 2, hind
limb weakness or paresis; 2.5, paralysis of at least one hind
limb or no weight bearing on hind limbs (dragging) but
with some leg movement; 3, complete hind limb paralysis;
3.5, hind limb paralysis, unable to right itself when placed
on its side; 4, hind limb paralysis and forelimb paresis; 4.5,
moribund; and 5, dead. Mice were euthanized at the end
of the day once they reached a score of 4.0 and immedi-
ately after reaching 4.5.
PET imaging studies
Naïve, control, and EAE mice were administered
[18F]FSPG (~ 9.25 MBq) or [18F]FDG (~ 4.63 MBq) via
tail vein injection. Mice receiving [18F]FDG were fasted
5–6 h prior to radiotracer administration and were all
given an equal volume of saline i.p. to prevent dehydra-
tion. PET imaging of anesthetized mice (1–2% isoflur-
ane) was performed using a microPET/CT hybrid
scanner (Inveon, Siemens). All PET images were recon-
structed using 2 iterations of three-dimensional ordered
subset expectation maximization algorithm (12 subsets)
and 18 iterations of the accelerated version of 3D-MAP
(i.e., FASTMAP), with a matrix size of 128 × 128 × 159.
Attenuation correction was applied to datasets from CT
image acquired just prior to each PET scan. No partial
volume corrections were performed. Dynamic PET scans
were acquired in list mode format over 90 min, starting
just prior to radiotracer injection. The resulting data was
sorted into 0.5-mm sinogram bins and 19 time frames
for image reconstruction (4 × 15 s, 4 × 60 s, 11 × 300 s).
For subsequent studies, static PET scans (10 min) were
acquired at ~ 70 min after injection of the radiotracer.
Image files were co-registered and analyzed with
VivoQuant (version 2.0, inviCRO) (Additional file 1:
Figure S1a–c). For VivoQuant analyses, the spine from
each mouse was isolated by use of the Otsu thresholding
technique and the obtained region of interest (ROI)
made immutable. An ROI of the spinal cord was then
drawn using the segmented spine as a guide. Corre-
sponding PET data were collected for the whole spinal
cord ROI, which was drawn from the caudal end of the
skull to the pelvis. For analysis of regional variations in
PET signal, the spinal cord was divided, using L1–L5 as
landmarks, into two cervical/thoracic and lumbar ROIs,
for which separate data were collected. For analysis of
the brain, a three-dimensional mouse brain atlas was fit-
ted to the PET/CT images and radioactivity concentra-
tions were obtained using ROIs for the major brain
regions (Additional file 1: Figure S1d). From this data,
the percentage of injected dose per gram (%ID/g) was cal-
culated for the spinal cord and atlas-based brain regions.
Tissue collection for ex vivo biodistribution,
autoradiography, and Western assays
While still under anesthesia, blood samples (200–400 μL)
were collected via cardiac puncture immediately prior to
perfusing mice with PBS. After mice had been euthanized,
tissues of interest were quickly removed at 110 min post-
injection of tracer.
For ex vivo biodistribution assays, tissues were placed
in tubes for gamma counting and weighed. Tissue-
associated radioactivity was assessed via an automated
gamma counter (Cobra II Auto-Gamma counter;
Packard Biosciences Co.) and decay-corrected to time of
tracer injection using diluted aliquots of the initial
administered dose as standards.
A subset of the spinal cords and brains were analyzed
via ex vivo digital autoradiography (n = 1 for EAE, score
3.0–3.5 and n = 1 for naïve mice per tracer). Following
perfusion, the brain was removed and embedded in opti-
mal cutting temperature (O.C.T.) compound (Tissue-
Tek, Sakura, USA). Subsequently, 20-μm-thick sagittal
brain sections were cut using a cryostat microtome
HM500 (Microm, Germany). The sections were
mounted on microscope slides (Fisherbrand Superfrost™
Plus Microscope Slides), air-dried for 10 min, and then
exposed to 18F-sensitive storage phosphor screens
(Perkin Elmer, USA) for 12 h at 4 °C. The image plates
were analyzed using a Typhoon 9410 Variable Mode
Imager (Amersham Biosciences, USA), and images were
visualized and processed by ImageJ (image processing
and analysis software in java, version 1.45s). Anatomy of
brain sections was confirmed by staining the exact same
sections with Nissl (cresyl violet acetate, Sigma Aldrich).
Briefly, dehydrated mounted sections were cleared in
xylene for 15 min, rehydrated, immersed in 0.5% cresyl
violet acetate (Sigma Aldrich) solution for 10 min,
rinsed, dehydrated, and coverslipped. Whole spinal cords
were also analyzed via autoradiography using same
storage phosphor screens and Typhoon imager.
For Western blotting, the spinal cords were cut into
thoracic/cervical and lumbar segments and the right
hemisphere of the brain was collected. Tissue samples
were immediately frozen in liquid nitrogen and stored
at − 80 °C.
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Western blotting
Tissue samples were homogenized using a total protein
extraction kit (BioChain) following the manufacturer’s
instructions. Protein concentration in lysates was deter-
mined by bicinchoninic acid (BCA) protein assay
(Pierce). Rabbit anti-xCT antibody (1:2000 dilution,
Novus NB300-318) was used according to a standard
western blotting protocol. After enhanced chemilumin-
escence (ECL) exposure, blots were washed and re-
probed with rabbit anti-actin antibody (Cell Signaling
Technology 4967S; 1:5000) as a loading control. To ver-
ify efficient extraction of xCT from the membrane dur-
ing tissue lysis, an anti-Na,K-ATPase antibody (Cell
Signaling Technology 3010S; 1:5000) was used as an
additional control for western blotting [16]. Blots were
scanned and signal was quantified using ImageJ
(National Institutes of Health).
Isolation and activation of primary human immune cells
Peripheral mononuclear blood cells (PMBCs) were iso-
lated from the whole blood of healthy donors (Stanford
Blood Center) via density gradient method (Ficoll Paque
PLUS, GE Healthcare). T cells or monocytes were iso-
lated from the PMBC fraction by negative selection
(Naïve Pan T Cell Isolation Kit/Monocyte Isolation Kit II,
Miltenyi Biotech). Purity of obtained fractions was assessed
by staining with CD3-VioBLue and CD14-FITC antibodies
(Miltenyi Biotech) for T cells and monocytes respectively.
The number of stained cells was then counted as a per-
centage of total cell number using a fluorescence micro-
scope (EVOS FL Cell Imaging System, Life Technologies).
T cells were maintained in TexMACS medium
(Miltenyi Biotech) and an aliquot was activated for 48 h
prior to the radiotracer uptake assay using a T Cell
Activation/Expansion Kit human (Miltenyi Biotech)
according to manufacturer’s instructions. Monocytes
were maintained in RPMI medium containing 10% heat-
inactivated FBS and 1% penicillin-streptomycin (all from
Life Technologies), and an aliquot was also activated for
48 h prior to the uptake assay with lipopolysaccharide
(LPS; 100 ng/mL, Escherichia coli O11:B4, Sigma Al-
drich). Activation was confirmed by assessing changes in
morphology of activated versus resting cells.
Cell uptake studies using primary human immune cells
Cells were counted, washed with Hank’s Balanced Salt
solution (HBSS) and re-suspended at 5–10 × 106 cells/mL
in HBSS. Five hundred microliters of aliquots of cell
suspensions were allowed to recover for 15 min at 37 °C
and 5% CO2. Five hundred microliters of pre-warmed
[18F]FSPG solution (1.5 MBq/mL in HBSS) was then added
to each tube. After incubation for 60 min at 37 °C and 5%
CO2, an aliquot of each cell suspension was layered over
200 μL of a 3:1 mixture of silicon oil and mineral oil in a
dolphin tube on ice as previously described [17]. Tubes
were spun for 3 min at 10,000g, and after freezing in liquid
nitrogen, the tips containing the cell pellets were cut into
gamma counter tubes. Cell-associated radioactivity was
assessed using a gamma counter (Cobra II Auto-Gamma
counter; Packard Biosciences Co.) and normalized to both
the total activity added and cell number.
Statistical analysis
Statistical analyses were performed using GraphPad
(version 6). Data are expressed as mean ± standard devi-
ation, unless otherwise indicated. Two-tailed Mann-
Whitney U tests were used for group comparisons and a
p value < 0.05 was considered significant. Two-tailed
Wilcoxon matched-pairs signed rank tests were used to
analyze repeated measurements in the longitudinal PET
study. A Bonferroni-adjusted p value of < 0.017 was con-
sidered significant when performing multiple compari-
sons. Correlation analyses were performed using linear
regression with goodness of fit designated by R2 value,
95% confidence levels.
Results
[18F]FSPG distribution and kinetics in EAE mice using
dynamic PET imaging
Time-activity curves obtained from dynamic PET data
(Additional file 2: Figure S2) revealed significantly higher
[18F]FSPG accumulation in the spinal cords of EAE com-
pared to those of naïve mice, from as early as 8 min after
tracer administration until the end of scan (p = 0.0043,
75 min post-injection), and a strong trend toward higher
uptake in the brain (p = 0.0571, 75 min post-injection).
While [18F]FSPG appeared to wash out of tissues from
naïve mice over time, it continued to accumulate in the
tissues of EAE mice, with a plateau observed in the spinal
cords starting at approximately 60 min after injection. An
imaging time point at 75 min post-injection was chosen
for all subsequent studies to allow for optimal tracer
accumulation in target tissues and clearance from non-
target tissues.
[18F]FSPG is more sensitive than [18F]FDG at detecting
molecular changes in the spinal cord and brain of EAE mice
Results from ex vivo biodistribution studies demon-
strated a significant elevation in [18F]FSPG uptake in
most EAE tissues compared to that in naïve mice (Fig. 1).
The greatest difference in [18F]FSPG tissue uptake was
seen in the spinal cord, with 1.07 ± 0.70 %ID/g in EAE
(n = 9, score 2.6 ± 0.9) and 0.05 ± 0.01 %ID/g in naïve
mice (n = 7), p = 0.0007. [18F]FSPG uptake was signifi-
cantly higher in the kidney and brain of EAE compared
to naïve mice (kidney: 67.8 ± 40.2 %ID/g vs. 6.7 ± 3.9
%ID/g, p = 0.0002; brain: 0.36 ± 0.11 %ID/g vs. 0.18 ± 0.07
%ID/g, p = 0.0059). In contrast, there was no significant
Hoehne et al. Journal of Neuroinflammation  (2018) 15:55 Page 4 of 12
difference in [18F]FDG uptake in most EAE tissues com-
pared to naïve mice (Fig. 1). The only significant difference
in [18F]FDG uptake was observed in the brain whereby
there was a lower accumulation in EAE mice (5.9 ± 0.2
%ID/g) compared to the brains of naïve mice (7.6 ± 0.7
%ID/g, p = 0.0079).
Ex vivo autoradiography images corroborated PET and
biodistribution findings, illustrating elevated [18F]FSPG
uptake in the spinal cords of EAE versus naïve mice
(Additional file 3: Figure S3A), and a moderate increase
in [18F]FDG uptake in distinct foci of EAE mice
(Additional file 3: Figure S3B). Qualitative autoradiog-
raphy of selected brains revealed visually higher
[18F]FSPG uptake in the cerebellum, hippocampus
(especially in the dentate gyrus), midbrain reticular
nucleus, optic chiasm, posterior complex of the thal-
amus, and sensory-related substructures of the medulla
of EAE compared to naïve mice. In contrast, there was
lower global [18F]FDG brain uptake in EAE versus naïve
mice, most notably in the cortex and olfactory bulb.
In vivo [18F]FSPG-PET imaging reveals increased xc- activity
in CNS tissues of EAE mice
Next, we performed a longitudinal study to characterize
[18F]FSPG uptake at the pre-symptomatic versus symp-
tomatic stage of disease. Since our pilot studies
highlighted a tenfold increase in [18F]FSPG uptake in
EAE mouse kidneys, alongside the increased uptake in
the spinal cord and brain, it appeared that [18F]FSPG
clearance might be affected in EAE mice. To address
this, we generated an additional group of control mice
with an identical immunization procedure to EAE mice
but without administration of MOG peptide antigen.
Additionally, we anesthetized mice just prior to PET im-
aging to allow additional time for clearance of the
radiotracer.
For longitudinal studies, mice underwent an initial static
PET/CT scan (~ 70 min post-injection of [18F]FSPG) at
the pre-symptomatic stage of disease on day 6 or 7 follow-
ing immunization (Fig. 2a shows disease time course and
PET imaging time points). Subsequent PET/CT imaging
and biodistribution was performed between days 14 and
18 post-immunization for control and EAE mice after the
latter reached a clinical score of 1.0–3.5.
Longitudinal studies revealed a significant increase
in [18F]FSPG-PET signal in the spinal cords of EAE
mice exhibiting no clinical symptoms (score 0, 1 week
post-immunization—Figs. 2 and 3; 1.2 ± 0.1-fold in-
crease, p = 0.0047) that later went on to develop pro-
nounced EAE within the next 4–8 days. After the
onset of disease, an even greater increase in
[18F]FSPG uptake was observed in the whole spinal
cord of EAE mice compared to that of controls (2.1
± 0.2-fold higher, p = 0.0002). Higher absolute
[18F]FSPG uptake in the lumbar versus cervical/thor-
acic spinal cord region was observed (Figs. 2 and 3),
Fig. 1 Ex vivo biodistribution of [18F]FSPG and [18F]FDG in EAE and naive mice. Ex vivo data was obtained 110 min after radiotracer injection
(n = 5–9, mean %ID/g ± SD) with magnified views of uptake in brain and spinal cord. EAE scores: 2.6 ± 0.9 and 3.2 ± 0.3 for [18F]FSPG and [18F]FDG
groups respectively. ***p 0.0001–0.001, **p 0.001–0.01
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while the fold-changes were in the same range (i.e.,
1.2 ± 0.1 [p = 0.0225] and 1.3 ± 0.1 [p = 0.0310] in week
1 and 2.0 ± 0.2 [p = 0.0005] and 2.3 ± 0.3 [p = 0.0002]
in week 2, for cervical/thoracic and lumbar spinal
cord, respectively). Although a trend toward higher
[18F]FSPG uptake in the spinal cord of mice with
lower clinical scores was observed, this was not statis-
tically significant. The post-symptomatic signal in the
whole spinal cord of EAE mice was 1.8 ± 0.2-fold
higher than the pre-symptomatic signal (p = 0.0002),
and the signal in control mice did not change over
time (p = 0.5625).
PET image analysis of brain regions revealed signifi-
cantly elevated uptake in the cerebellum, hippocampus,
medulla, and midbrain of symptomatic EAE versus con-
trol mice—with the most marked fold-changes in the
a
b
c
d
Fig. 2 Elevated [18F]FSPG-PET signal in EAE mice at early stages of disease. a Disease scores of mice induced with EAE over 18 days. Arrows
indicate PET/CT imaging time points and scores are represented as mean score ± SEM. b Representative sagittal PET/CT images of control,
pre-symptomatic EAE (score 0), and EAE mice with early stage disease symptoms (score 1.5). Arrows indicate spinal cord uptake. Bl—bladder,
Br—brain, H—Haderian glands, I—immunization site, K—kidneys, S—salivary glands. c Representative sagittal PET/CT images of identical brain
sections of control, pre-symptomatic EAE (score 0), and symptomatic EAE (score 1.5) mice. Cb—cerebellum, HC—hippocampus, Mb—midbrain,
Med—medulla. Dotted lines highlight region containing possible meningeal vessel(s). d Representative PET/CT volume rendering technique (VRT)
image of EAE mouse (score 1.5). PET signal outside spinal column and skull was removed for better visualization of [18F]FSPG uptake in areas of interest
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cerebellum (Table 1). Interestingly, there was a region of
radiotracer uptake present in the PET images of EAE
mice, which appeared to be just outside the brain
(dotted lines in Fig. 2c, see Additional file 4: Figure S4
for coronal brain slices) and became more intense when
mice became symptomatic.
Elevated [18F]FSPG-PET signal in EAE CNS tissues
compared to control mice was further confirmed by ex
vivo gamma counting of tissues from the same mice
(Additional file 5: Fig. S5). Spinal cord [18F]FSPG uptake
was 0.69 ± 0.35 %ID/g (n = 9) in EAE compared to 0.04
± 0.01 %ID/g in control mice (n = 8, p < 0.0001), with a
similar fold-difference (16.2 ± 3.2) to what we previously
observed in pilot studies using naïve mice. Brain uptake
was also significantly higher in EAE mice compared
to controls (0.15 ± 0.05 %ID/g vs. 0.07 ± 0.03 %ID/g,
2.2 ± 0.4-fold, p = 0.0012). Other significant differences
in [18F]FSPG uptake were observed in the blood
(EAE: 0.37 ± 0.15 %ID/g vs. control: 0.20 ± 0.02 %ID/g,
p = 0.0044) and kidneys (EAE: 6.7 ± 2.4 %ID/g vs.
control: 3.8 ± 1.2 %ID/g, p = 0.0155).
[18F]FSPG-PET signal correlates with elevated xCT protein
levels in EAE CNS tissues
xCT protein levels were assessed by Western blot of the
brain, cervical/thoracic, and lumbar cord tissues
collected after [18F]FSPG-PET/CT imaging (Fig. 4 and
Additional file 6: Figure S6). Results from these studies
revealed a strong correlation between [18F]FSPG-PET
signal and xCT protein levels in the cervical/thoracic
spinal cord (R2 = 0.80, p = 0.0002), and a moderate cor-
relation in the lumbar spinal cord (R2 = 0.46, p = 0.0143)
and brain (right hemisphere, R2 = 0.6664, p = 0.0012).
xCT expression in the brain and cervical/thoracic and
lumbar spinal cords from control versus naïve mice were
not significantly different (p > 0.05, n = 3–4 per group;
Additional file 7: Figure S7).
[18F]FSPG uptake is increased in isolated primary human
immune cells upon activation
Finally, we investigated the uptake of [18F]FSPG in primary
human T cells and monocytes; the immune cell types
which are implicated in the pathogenesis of EAE. Data
from these studies revealed a dramatic increase in
[18F]FSPG uptake in activated compared to resting T cells
(75-fold, p < 0.0001) and in activated versus resting human
monocytes (2.3-fold, p = 0.0079, Fig. 5). The absolute level
of [18F]FSPG uptake in activated monocytes (0.284 ±
0.006%uptake/105 cells), however, was fourfold higher than
that in activated T cells (0.070 ± 0.004%uptake/105 cells).
Discussion
Cystine/glutamate antiporter, xc-, has been implicated in
several neurological disorders and, specifically, in MS as
a mediator of glutamate excitotoxicity and immune
regulation [4]. Recent studies demonstrated that the
a b
c d
Fig. 3 Quantification of [18F]FSPG-PET signal in CNS tissues of pre-symptomatic and symptomatic EAE versus control mice. Static PET imaging
was performed 75 min post-injection of radiotracer (n = 6–10) and signal was quantified in the a whole spinal cord, b cervical/thoracic spinal cord,
c lumbar spinal cord, and d whole brain. ***p 0.0001–0.001, **p 0.001–0.01, *p 0.01–0.05, NS—non-significant
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xCT subunit of system xc- (responsible for the activity of
this antiporter) is upregulated in postmortem CNS tis-
sues from both MS patients and MS rodent models [6]
and that it might be a promising PET imaging biomarker
of disease progression in EAE rats [8].
Here, we show that [18F]FSPG-PET enables the
sensitive detection of alterations in xCT protein levels/
xc- activity in EAE mice at different stages of disease in
vivo. Most notably, [18F]FSPG-PET showed potential for
the early detection of MS due to its increased uptake in
Table 1 Uptake values (%ID/g) for different brain regions in pre-symptomatic and symptomatic mice and fold differences with
respect to the same quantitation in control mice
Brain regions 1 week post-immunization (pre-symptomatic mice) 2 weeks post-immunization (mice with clinical signs of EAE)
%ID/g in EAE mice Fold-differences EAE vs. controls %ID/g in EAE mice Fold-differences EAE vs. controls
Whole brain 0.38 ± 0.04 1.1 ± 0.1NS 0.48 ± 0.09 1.3 ± 0.2NS
Cerebellum 0.36 ± 0.06 1.1 ± 0.1NS 0.45 ± 0.10 1.6 ± 0.2**
Cortex 0.30 ± 0.04 1.1 ± 0.1NS 0.34 ± 0.08 1.2 ± 0.2NS
Hippocampus 0.32 ± 0.04 1.1 ± 0.1NS 0.38 ± 0.09 1.4 ± 0.2*
Hypothalamus 0.76 ± 0.13 1.2 ± 0.1* 0.97 ± 0.19 1.2 ± 0.2NS
Medulla 0.54 ± 0.08 1.1 ± 0.1NS 0.67 ± 0.17 1.5 ± 0.2*
Midbrain 0.29 ± 0.04 1.1 ± 0.1NS 0.35 ± 0.10 1.5 ± 0.2*
Olfactory bulb 0.64 ± 0.15 1.1 ± 0.1NS 0.97 ± 0.30 1.3 ± 0.3NS
Pallidum 0.45 ± 0.07 1.2 ± 0.1* 0.61 ± 0.13 1.2 ± 0.3NS
Pons 0.44 ± 0.07 1.0 ± 0.1NS 0.71 ± 0.25 1.3 ± 0.3NS
Striatum 0.34 ± 0.04 1.1 ± 0.1NS 0.42 ± 0.09 1.2 ± 0.2NS
Thalamus 0.28 ± 0.05 1.1 ± 0.1NS 0.32 ± 0.07 1.3 ± 0.2NS
NS not significant
Absolute [18F]FSPG uptake in brain regions as measured by PET, 75 min p.i. of radiotracer in EAE mice (n = 6–10, mean %ID/g ± SD) and fold
differences ± SEM versus controls with indices indicating significance by Mann-Whitney test: **p = 0.001–0.01, *p = 0.01–0.05
a b
c d
Fig. 4 Significant correlation between xCT protein levels in CNS tissues and in vivo PET signal. a Representative Western blot with actin and NaK-ATPase
as loading controls (Ctrl). Correlation between xCT protein levels (determined by densitometric Western analysis) and [18F]FSPG uptake (determined by
PET quantification) in the b cervical/thoracic spinal cord (SC), c lumbar SC, and d brain. ***p 0.0001–0.001, **p 0.001–0.01, *p 0.01–0.05
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the spinal cord of EAE mice even at the pre-
symptomatic stage of disease. This is the first report that
[18F]FSPG-PET signal is elevated at this early stage of
EAE, thus emphasizing the utility of [18F]FSPG-PET as a
technique for characterizing the in vivo role of this anti-
porter in the early stages of EAE disease development.
Previously reported studies performed by Martin and
colleagues using [18F]FSPG-PET for imaging xc- in EAE
rats did not detect increased PET signal at the pre-
symptomatic stage of EAE; however, they did not image
control or naïve rats for direct comparison [8].
Here, [18F]FSPG showed greater sensitivity than
[18F]FDG in detecting metabolic changes in the EAE
spinal cord, exhibiting a 21-fold difference in uptake in
EAE vs naïve mice in ex vivo biodistribution studies.
[18F]FDG biodistribution results from EAE versus naïve
and control mice were comparable to those previously
reported by Radu et al. [18], Martin et al. [8], and Buck
et al. [11]. As in our study, the latter found no statistical
significance between groups. The heterogeneous pattern
of [18F]FDG uptake in distinct inflammatory infiltrates
in the spinal cords of EAE mice and significant decrease
in [18F]FDG uptake in the brain, observed by autoradiog-
raphy, was also consistent with previous findings [14, 15].
Grassiot and colleagues reported hypometabolism in MS
patients and postulated that low [18F]FDG brain uptake is
likely due to reduced brain volume and disturbed glucose
metabolism in these patients [19]. One reason for the
difference in sensitivity between [18F]FSPG and
[18F]FDG is likely due to their different uptake mecha-
nisms, and therefore the different biological phenom-
ena these tracers measure. [18F]FDG is taken up via
glucose transporters and subsequently trapped in cells
following phosphorylation by hexokinase II, while
[18F]FSPG is taken up via xc- and retained in cells by
an unconfirmed mechanism [15]. It is possible that al-
terations in xc- activity are more striking than alter-
ations in glucose metabolism in rodent EAE.
Both PET and autoradiography images indicated
higher accumulation of [18F]FSPG in the cerebellum,
hippocampus, medulla, and midbrain of EAE mice, all
regions where demyelinating lesions and tissue damage
can occur in MS patients [20] and EAE mice [21]. These
findings correspond well with what is known about the
spatial distribution of infiltrating immune cells, known
to overexpress xCT, in the CNS of EAE rodents. For ex-
ample, Brown and colleagues reported marked infiltra-
tion of CD3-positive T cells and also the presence of
activated microglia in the sensory-related substructures
of the medulla and cerebellar peduncles of EAE mice
[21]. We additionally observed a region with tracer up-
take of variable intensity just outside the brain. This sig-
nal could possibly be associated with [18F]FSPG signal in
CD3-positive T cells (or other infiltrating immune cells)
in the meninges/subarachnoid space [22] or a meningeal
lymphatic vessel [23]—all of which have been shown to
be sites where T cells can reside as they mobilize and
cross the BBB.
We observed significantly higher [18F]FSPG levels in
the blood and kidneys of EAE mice compared to naïve
mice. The higher kidney uptake is likely due to impaired
renal function in EAE mice, a co-morbidity with low
prevalence in MS patients [24], leading to inferior excre-
tion ability [25]. The increased level of [18F]FSPG in the
blood is most likely due to increased circulating acti-
vated monocytes in EAE mice, which are known to have
elevated xCT protein levels [6]. It is important to note
that the measured difference in [18F]FSPG uptake levels
in CNS tissues of EAE versus naïve/control mice became
even more pronounced after removal of the blood via
perfusion (as seen in ex vivo biodistribution data) com-
pared to that in in vivo PET data. Hence, it appears that
the increased blood pool activity observed in EAE mice
partially obscures the specific signal increase. As previ-
ously demonstrated by Ayzenberg et al., the effect of
EAE immunizations must be considered when
Fig. 5 [18F]FSPG uptake in resting and activated primary human immune cells. In vitro accumulation of [18F]FSPG in isolated primary human T
cells and monocytes (n = 5–11, mean %ID/g ± SD). ****p < 0.0001, **p < 0.01
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interpreting bulk imaging signals by comparing to ap-
propriate controls (i.e., control mice which undergo in-
complete immunization with CFA emulsion and
pertussis toxin while omitting MOG peptide, rather than
using naïve mice) in order to prove specificity of the
readout [26]. In this study, we demonstrated specificity
of the observed in vivo [18F]FSPG-PET signal by using
such control mice and also by performing Western blot-
ting of brain and cervical/thoracic and lumbar spinal
cord to investigate how well the PET signal reflected al-
terations in xCT expression. A significant correlation
was found between the levels of xCT protein and the
PET signal in these tissues, thus verifying the utility of
[18F]FSPG-PET for investigating in vivo alterations in
xCT over time in this mouse model.
As a prelude to clinical evaluation of [18F]FSPG in MS
patients, we investigated whether a single immune cell
population might be primarily responsible for the elevated
tissue uptake of [18F]FSPG. A recent study by Evonuk and
colleagues linked xCT expression on activated T cells with
CNS infiltration and disease progression, highlighting the
possible utility of xc- as a theranostic target in MS [27].
Numerous studies have highlighted considerable infiltra-
tion of CD68-positive cells (macrophages/microglia),
monocytes, as well as T cells in spinal cord and brain le-
sions of EAE rodents [6]. We performed tracer uptake
studies in isolated primary human T cells and monocytes
to gain clarity on the relative accumulation of [18F]FSPG
in each cell type. Results from these studies revealed a dra-
matic 75-fold increase in [18F]FSPG uptake in activated
versus resting T cells and a comparatively modest, yet sig-
nificant, 2.3-fold increase in activated versus resting
monocytes. These results are in agreement with studies
which have shown that T cells only express xCT in the ac-
tivated state [28], while monocytes constitutively express
xCT with upregulation upon activation [6]. CD11b/CD45-
positive cells account for the majority of immune cells
found in the CNS tissue of EAE mice (40–56% at all stages
of disease), whereas cells of the T cell lineage represent a
lower fraction (approximately 17%) [29]. Together with
the higher absolute tracer uptake in monocytes compared
to T cells, it is suspected that both types of immune cells
likely contribute to the increased [18F]FSPG tissue signal.
Moreover, microglia/macrophages likely also contribute to
the observed elevated [18F]FSPG signal, as [18F]FSPG-PET
signal in EAE rats was significantly reduced after select-
ively depleting microglia via intracerebroventricular injec-
tion of liposome-encapsulated clodronate [8]. Further
characterization of the immune cell populations (both
murine and human) predominantly responsible for the in-
creased [18F]FSPG tissue uptake at different stages of dis-
ease progression are planned and will likely provide
insight into the spatiotemporal dynamics of immune cells
and their oxidative stress levels in MS.
Conclusion
In summary, we have shown that [18F]FSPG-PET is a
promising imaging technique for non-invasively moni-
toring xc- activity in EAE mice, both at very early stages
of disease and throughout progression, and holds great
potential as a sensitive tool for investigating the links be-
tween oxidative stress, immune cell trafficking, and clin-
ical symptoms of MS. Using this technique, we gained
new insights into the in vivo spatiotemporal dynamics of
xc- activity in pre-symptomatic and symptomatic EAE.
Future studies will involve evaluating the use of
[18F]FSPG-PET for predicting/monitoring response to
novel antioxidant therapeutics, which are gaining inter-
est as neuroprotective agents in MS.
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Additional file 1: Methods for defining regions of interest (ROIs) in CNS
using VivoQuant image analysis software. (a) Spine/vertebrae (blue) was
segmented out using Otsu Thresholding. (b) The spine ROI was made
immutable, and the thoracic/cervical (orange) and lumbar (yellow) spinal
cord ROIs were highlighted using the 3D ROI drawing tool. (c) The spine
ROI was then removed, leaving only the ROIs for the lumbar and
thoracic/cervical spinal cords. (d) Brain ROIs of interest were obtained
using a 3D mouse brain atlas: medulla (yellow), cerebellum (light blue),
midbrain (dark green), pons (light pink), cortex (gray), thalamus (red),
hypothalamus (light purple), hippocampus (dark purple), striatum
(magenta), pallidum (peach), and olfactory bulbs (maroon). After fitting
the 3D mouse brain atlas ROI to the CT, the amount of activity in each
region was obtained in nCi/cm3 and then converted to %ID/g. (e) ROI of
the right hemisphere was used for correlation with Western blot data,
which was performed using only the right brain hemisphere for each
mouse. (DOCX 749 kb)
Additional file 2: Dynamic PET imaging of [18F]FSPG uptake in the
spinal cords (a) and brains (b). Time-activity curves represent average
counts from a dynamic 90-min scan in EAE and naïve mice. Data are
mean ± SEM (n = 3–7 animals per group). (DOCX 119 kb)
Additional file 3: [18F]FSPG and [18F]FDG ex vivo autoradiography of EAE
versus naïve mice. Representative autoradiography images of whole spinal
cords and sagittal brain sections from EAE (score 3.0–3.5) versus naïve mice
collected ~ 110 min after injection of (a) [18F]FSPG and (b) [18F]FDG. The
same brain sections were stained with Nissl and overlayed with the
corresponding autoradiographic images. Cb—cerebellum, Ctx—cortex,
HC—hippocampus, Med—medulla, Ob—olfactory bulb, Thal—thalamus.
Dotted lines highlight region containing the optic chiasm. (DOC 184 kb)
Additional file 4: Adjacent coronal brain PET/CT images of a
representative EAE mouse. Images of EAE mouse (score 1.5) were
acquired ~ 75 min after injection of [18F]FSPG. Images are arranged
beginning with caudal slices through to more rostral regions of the brain.
Dotted lines highlight region of [18F]FSPG accumulation in meninges
and/or in possible meningeal vessel(s) or subarachnoid space.
(DOCX 2608 kb)
Additional file 5: Ex vivo biodistribution of [18F]FSPG in EAE versus
control mice (a) with magnified views of the brain (b) and spinal cord (c)
data (n = 8–10, mean %ID/g ± SD). Data was collected 110 min after
injection of radiotracer and mean score of EAE mice was 2.4 ± 0.8.
Significance determined Mann-Whitney test with ****p < 0.0001,
***p 0.0001–0.001, **p 0.001–0.01, *p 0.01–0.05. (DOCX 128 kb)
Additional file 6: Complete raw/unedited images of Western blots
shown in Fig. 4a. Blot after incubation with anti-xCT antibody (a) the
same blot having been re-probed with loading controls anti-actin and
anti-Na,K-ATPase antibody (b). (DOCX 10919 kb)
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Additional file 7: xCT protein levels in CNS tissues do not differ
between control and naïve mice. SC = spinal cord. Data are represented
as mean xCT/Na,K-ATPase signal ± SD (n = 3–5). Significance determined
by Mann-Whitney test with NS = not significant. (DOCX 65 kb)
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